Major study launches to track heart risks in transgender people on hormones
NCT ID NCT07187947
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 500 transgender adults who have been on gender-affirming hormone therapy for at least a year. Researchers will measure changes in blood pressure, cholesterol, body composition, and other heart health markers. The goal is to understand the long-term cardiovascular effects of hormone therapy and improve care for transgender individuals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gender-affirming hormone therapy (estradiol, antiandrogens, or testosterone)
What this could lead to
If successful, this study could provide clear data on how hormone therapy affects heart health in transgender individuals, helping doctors tailor safer treatment plans.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new drug or cure. Results may take years and could still leave many questions unanswered.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR (CV) RISK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
RECRUITINGBologna, BO, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••